| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.47 | 6e-43 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.43 | 6e-36 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.35 | 2e-24 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.3 | 2e-20 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.33 | 2e-20 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.38 | 2e-17 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | 0.25 | 1e-16 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | 0.4 | 5e-16 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.42 | 1e-15 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.24 | 9e-14 |